摘要
目的探讨培美曲塞联合卡铂对中老年晚期非小细胞肺癌患者的临床效果与毒副作用。方法选取2012年8月~2013年10月收治的中老年晚期非小细胞肺癌患者64例为研究对象,将其随机分为观察组（n=32）和对照组（n=32）。观察组患者采用培美曲塞联合卡铂进行治疗,对照组患者采用吉西他滨联合卡铂进行治疗,比较两组患者的临床效果和毒副作用发生情况。结果观察组患者治疗总有效率为43.75%,高于对照组患者的40.62%,但差异无统计学意义（χ2=0.453,P〉0.05）;观察组患者血液学毒性、消化道毒性以及其他并发症发生率均显著低于对照组,差异具有统计学意义（P〈0.05）;两组患者的肿瘤进展时间（TTP）和一年生存率基本相当,差异无统计学意义（P〉0.05）。结论培美曲塞联合卡铂治疗中老年晚期非小细胞肺癌疗效显著,能够明显改善患者病情,延长患者的生存期,且毒副反应少。
Objective To investigate the clinical efficacy of pemetrexed and carboplatin in elderly patients with advanced non-small cell lung cancer. Methods 64 cases of elderly patients with advanced non-small cell lung cancer from August 2012 to October 2013 were enrolled in the study, and divided into two groups randomly：the observation group（n = 32）and the control group（n = 32）. Patients in the observation group were treated with pemetrexed plus carboplatin, and patients in the control group were treated with gemcitabine and carboplatin. Results The total effective rate in observation group was 43.75%,which was slightly higher than that in control group（40.62%）, while the difference was not significant（χ2 = 0.453, P〉 0.05）. The hematologic toxicity,gastrointestinal toxicity and other complications in observation group were significantly lower than those in control group（P〈0.05）, The tumor progression（TTP） and one year survival rate in both groups were roughly equal（P 〉0.05）. Conclusion The theraphy of pemetrexed plus carboplatin was effective in the treatment of elderly patients with advanced non-small cell lung cancer, which can significantly prolong survival and improve the patient＇s condition with mild toxicity, and it is worthy of clinical application.
出处
《中国处方药》
2016年第6期8-10,共3页
Journal of China Prescription Drug
关键词
培美曲塞
卡铂
晚期非小细胞肺癌
中老年
Pemetrexed
Carboplatin
Advanced non-small cell lung cancer
Elderly patients
